Tumor progression is affected by a wide variety of components within the tumor microenvironment, and the importance of neutrophils in glioma has yet to be fully characterized.
Introduction
Gliomas are the most common type of primary brain tumors in adults and classified into four grades by the world Health Organization (WHO) according to their degree of malignancy and histologic features (1) . For patients with high grade gliomas (HGGs), such as glioblastoma, the prognosis remains poor with a short survival time (1, 2) . Patients with low grade tumors have a comparative longer-term survival, but nearly all low-grade tumors progress to high-grade malignancy (3) . Identifying the key contributors and molecular pathways that result in tumor progression is the focus of intense investigation because inhibition of malignant progression of glioma has the potential to significantly extend patient survival.
Over the past two decades, advances made in molecular technologies such as microarray technologies and genome sequencing have made it possible to evaluate the molecular and genetic changes in malignant brain tumors. Recent gene expression profiling studies have revealed 3 to 4 molecular subclasses of HGGs based on differential gene expression (4, 5) .
One tumor subtype is characterized by expression of neural progenitor markers (proneural, PN), which is enriched in low grade gliomas (LGGs) (6) , is associated with longer survival, whereas malignant glioma with a mesenchymal (MES) signature are aggressive, commonly coincide with disease recurrence, resistant to chemothrepy, and is associated with a shorter survival time. In addition, resistance to chemotherapy is also seen in gliomas that were originally defined as proneural and later have increased mesenchymal genes expression, suggesting a shift to the mesenchymal subtype over time (4, 5) . This shift from proneural to mesenchymal transition (PMT) in glioblastoma may drive its aggressive behavior and eventually cause chemotherapy failure (7) . Currently, it is unknown what drives this PMT in glioblastoma.
Research.
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Author Manuscript Published OnlineFirst on November 15, 2013; DOI: 10.1158/1078-0432.CCR- Recent evidence provided by our group and others point to tumor microenvironment components as potential participants in the generation of tumor malignancy and chemoresistance (7) (8) (9) (10) (11) . The tumor microenvironment contains large populations of cancerrelated inflammatory cells including tumor associated neutrophils (TAN). In gliomas, increased infiltration of neutrophils has been observed in HGGs comparing to LGGs (12) . Resistance to chemotherapy is also associated with increased infiltration of neutrophils. Our previous work shows that glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration and mesenchymal transition, indicating a positive correlation between them (7).
Similar findings have been reported for other tumors (13, 14) , suggesting that targeting TANpromoting tumor progression can be a universal method to overcome drug resistance and tumor recurrence. Shojaei with anti-myeloid cell therapy inhibits growth of refractory tumors more effectively than anti-VEGF alone (15, 16) . Recent work by Acharyya et al. showed that inhibition of neutrophil recruitment augments the efficacy of chemotherapy against breast tumors and particularly against lung metastasis (8) . It has been reported that blocking TAN infiltration into tumor tissues can influent several key aspects of tumor progression, including tumor growth (17) (18) (19) , angiogenesis (16, 20, 21) and metastasis (8, 11 ). Identifying the mechanisms by which TAN promote tumor progression and the genetic characteristics associated with these phenotypic changes is essential to identify the key regulators of glioblastoma progression and thus guide the development of new therapies to overcome resistance.
In this study, we make use of an in vitro co-culture model to investigate the interaction between glioma cells and neutrophil progenitor cells, especially how neutrophil influence glioma phenotypes and signaling pathways. We found that co-culture of neutrophil and glioma stem cells increases the expression of S100A4 in glioma cells, which was also up-regulated in anti- VEGF resistant tumors. Down-regulating neutrophil-promoting expression of S100A4 can mitigate the neutrophil-mediated malignant phenotype in vitro and in vivo. Furthermore, S100A4 depletion prolongs the survival of anti-VEGF treated animals and partially reduces glioblastoma resistance to anti-VEGF therapy.
Materials and Methods
Brain Tumor Tissue Microarray. A human glioma tissue microarray was constructed using formalin-fixed, paraffin-embedded archival tissue blocks as described previously (22) Mayer's hematoxylin nuclear staining was used as a counterstain. An intensity score was assigned to each sample that represented the average numbers of the positive staining on an arbitrary scale of 0 to 5. Statistical analysis was done using a Kruskal-Wallis analysis of ranks.
Cell culture. Glioma stem cell line GIC23, GIC11, GIC2 and GIC20 were obtained from Dr.
Howard Colman (Department of Neuro-Oncology, M.D. Anderson Cancer Center, Houston, TX).
GIC cells were maintained in suspension in DMEM containing epidermal growth factor, basic fibroblast growth factor (bFGF), and B27 (Invitrogen) at 37°C in 5% CO 2 atmosphere. Neutrophil progenitor cell line CRL-11422 (AACR) was cultured in Iscove's modified Dulbecco's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate containing 10 ng/ml murine granulocyte macrophage colony stimulating factor (GM-CSF) 80%; heat-inactivated Immunoblot analysis. Cells were lysed in an ice-cold lysis buffer containing 50 mM Tris-Cl, pH 7.5, 100 mM NaCl, 1 mM EDTA, 1% TritonX-100, 1 mM PMSF, 1 μg/ml leupeptin, and 1 μ/ml pepstain A. The protein concentration in the supernatant was determined using a BCA protein assay (Pierce, Rockford, IL, USA). Samples were subjected to 8-12% SDSpolyacrylamide gel electrophoresis, and the separated proteins were electrophoretically transferred to nitrocellulose membranes. Blots were incubated with the primary antibody against cyclin D1 (1:1000, CST), cyclin D2 (1:1000, CST), c-myc (1:1000, CST), Tubulin (1:3000, Sigma), Ykl-40 (1:1000, Santa Cruz Biotechnology), MMP2 (1:1000, Chemicon-Millipore), nestin (1:1000, abcam) or S100a4 (1:1000, abcam). The membranes were then incubated with horseradish peroxidase-linked secondary anti-rabbit or anti-mouse antibodies (bio-rad).
Invasion assay. Matrigel Basement Membrane Matrix (BD Labware) was used to perform the in vitro cell invasion assays. Cells were pretreated with bevacizumab for 72 h. Transwell inserts for 24-well plates were coated with diluted Matrigel, and cells were added in triplicate to the transwells. Serum-free medium was added to the bottom of the plate. Cells were allowed to invade for 24 h at 37°C. The filters were then fixed and stained with 0.1% crystal violet in 20% methanol. The invasive cells were visualized using bright-field microscopy. Transwell ) were implanted intracranially into nude mice (12 mice per group). The mice were euthanized at 3, 6, 9, 11 week, and their brains were removed and processed for analysis. All experiments were approved by the Institutional Animal Care and Use Committee of The University of Texas M. D. Anderson Cancer Center. Tumor volume analysis was done using an unpaired two-tailed Student's test and groups were compared using the log-rank test. P < 0.05 was determined to be significant.
Immunohistochemistry.
Paraffin sections from xenografts were used for immunohistochemical analysis. The slides were deparaffinized and subjected to graded rehydration. After blocking in 5% serum and an antigen retrieval step (citrate buffer, pH 6.0), the slides were incubated with the primary antibodies overnight at 4°C. After washing in PBS with Tween 20, primary antibody reactions were detected using the Vectastain ABC kit (Vector Laboratories) with the respective secondary antibody.
Transfection. Cells were plated at a density of 3×10 5 /6 well plate 3 h prior to transfection.
Transfection was carried out using HyFect reagents according to the vendor's instructions.
Transfected cultures were selected with puromycin (5 μg/ml) for 10-14 days. At that time, antibiotic-resistant colonies were picked, pooled and expanded for further analysis under selective conditions. The pGIPZ control was generated with control oligonucleotide GCTTCTAACACCGGAGGTCTT. pGIPZ S100a4 shRNA was generated with TGCTCAGCATCAAGCACGT and TGAGCTTGAACTTGTCACC. Cancer Center (website accessed on 25th, April, 2013) . The levels of expression of S100A4 were evaluated in the different TCGA glioblastoma subtypes (Glioblastoma, Nature 2008). For each glioma subtype, patients were divided into two groups based on gene expression (Z-score < or ≥ 2). Kaplan Meier curves were generated using these data. The difference in survival between patients with high and low expression of S100A4 was calculated for each subtype.
Results

Neutrophil infiltration is correlated with glioma grade and tumor progression.
A human glioma tissue microarray (TMA) was used to evaluate for the presence of neutrophil infiltration using immunohistochemical staining for myeloperoxidase-positive (MPO). The numbers of MPO-positive cells for each tumor sample were calculating from grade II, III and IV glioma. Eighty-six percent of all glioma samples in our TMA (n=232) had some evidence of neutrophil infiltration (Fig. 1A) . Grade IV glioblastoma specimens had the highest numbers of infiltration neutrophil (number of neutrophil>10/200X HPF (high powered field)) ( Fig. 1A and Supplementary data Table 1 ). The level of neutrophil infiltration was significantly positively correlated with glioma grade. To confirm the level of neutrophil infiltration in murine models of glioma, we evaluated the numbers of neutrophils infiltrated into tumor xenografts injected into the brain of nude mice. The number of murine neutrophils characterized by the marker Ly-6B.2 (24, 25) increased during tumor growth and progression (Fig. 1B) .
Neutrophils promote the proliferation of glioma stem cells (GICs).
To identify the effects of neutrophils on tumor cells, we performed in vitro co-culture of glioma stem cells (GICs) with neutrophil progenitor cells (MPRO cells, CRL11422, ATCC). After 2 days of co-culture, the numbers of GFP-positive GIC11 cells were significantly increased comparing to controls (Fig. 2A) . Condition media (CM) collected from MPRO cells (24 hour serum-free culture medium) also increase the numbers of GICs (Fig. 2B) , suggesting that secreted factors from neutrophils may be partially responsible for the tumor proliferating effects.
Further evaluation by Propidium Iodide (PI) staining identified that the increase in cell number resulted from both a decrease in GIC apoptosis (Fig. 2C) and an increase in cell proliferation (Fig. 2D) . Western blot data demonstrated that CM up-regulated the expression of proliferation related proteins cyclin D1, cyclin D2 and c-myc (Fig. 2E) . In addition, CM increased the phosphorylation of Akt and Erk (Supplementary data Fig. 1 A) . Blocking Akt and Erk pathway activation by their inhibitors decreased the expression of cyclin D1 and c-myc induced by CM (Supplementary data Fig. 1 B) . These data indicate that, at least in our in vitro model, factors secreted by neutrophils promote GIC proliferation.
Neutrophils promote a mesenchymal phenotype.
We next investigated the effect of neutrophils on the ability of GIC invasion. A Matrigel transwell assays showed an increase in transwell migration/invasion for GICs when co-cultured with MPRO cells compared to controls (Fig. 3A) . GIC cells in culture demonstrated a spindle-shaped morphology, which is a typical morphology for mesenchymal cells (26) . When co-culture with MPRO cells (Fig. 3B) . Consistent with a more mesenchymal phenotype, Western blots showed increased expression of mesenchymal markers YKL-40 and MMP2, and less expression of Nestin, a proneural marker following co-culture (Fig. 3C) . To confirm the effects of neutrophils on GICs and to investigate the underlying mechanisms by which neutrophils promote a mesenchymal glioma phenotype, we performed gene expression analysis of GIC23 treated with or without MPRO cells. IPA analysis (Supplementary data Fig. 2) showed a significant shift towards a mesenchymal gene signature and increased cell mobility in the co-culture group compared to the control group. These data indicate that neutrophils promote a mesenchymal shift in GICs. In addition, gene expression analysis demonstrated that neutrophils also promote an increase in genes related to cell division processes, consistent with the results presented in Fig. 2 .
Neutrophils promote a malignant glioma phenotype through S100A4.
In our previous work, we found glioblastoma resistance to anti-VEGF therapy was associated with neutrophil infiltration and a mesenchymal phenotype (7) . Gene expression profiling data from these experiments also identified (Fig. 4A) multiple genes that were up-regulated during the development of resistance. Several of these genes may be involved in the regulation of neutrophil-mediated mesenchymal transformation. One of the candidate genes S100A4 was found to be highly expressed in GIC with a mesenchymal phenotype (Fig. 4B, GIC2 and GIC20), whereas no expression was observed in GICs of the proneural subclass (Fig. 4B,   GIC11 and GIC23). To identify the role of S100A4, we developed a stable GIC23 cell line with a specific shRNA to S100A4 (Fig. 4C) .
Consistent with the gene expression analysis, GICs co-culture with neutrophils increased S100A4 expression, which was not observed in the S100A4 knock down cell line. Although down regulation of S100A4 did not affect neutrophil-mediated proliferation (Fig. 4E) , neutrophil promotion of tumor cell migration (Fig. 4F) and YKL-40 expression (Fig. 4G) were inhibited by S100A4 knock down. To evaluate the impact of S100A4 on tumor growth in vivo, we then coinjected neutrophils with control shRNA or S100A4 shRNA GIC23 into nude mice. Consistent with the in vitro data, neutrophils co-injection increased human S100A4 expression in tumor tissue, while almost no human S100A4 staining was observed in the S100A4 knock down group (Supplementary data Fig. 3A) . Our data showed that co-injection of neutrophils with control GIC23 cells enhanced tumor growth, an effect that was significantly blunted by using cells with S100A4 knock down (Fig. 5A) . Increased YKL-40 expression was also observed in control cells injected concurrently with neutropihls, but not in S100A4 knock down cells with neutrophils (Fig.   5B ). Finally, neutrophil co-injection increased vascularization in control GICs group but not in the S100A4 knock down group (Fig. 5C ). Taken together, these data indicate that S100A4 was partially responsible for neutrophil-mediated glioma progression.
S100A4 depletion increases the efficacy of anti-VEGF therapy in gliomas
Since S100A4 depletion may block neutrophil-mediated mesenchymal transformation, which is a prominent feature of anti-VEGF resistant tumors, we next investigated whether S100A4 depletion would improve the efficacy of anti-VEGF therapy. Our survival study in animals demonstrated that mice treated with bevacizumab had a longer survival time than the no treatment group [P=0.0044, log-rank (Mantel-Cox) test; Fig. 6A ], and S100A4 depletion further prolonged survival [P=0.0137, log-rank (Mantel-Cox) test; Fig.6A ]. Immuno-staining data showed that the specific shRNA dramatically inhibited S100A4 expression in tumor cells (Supplementary data Fig. 3B ), but this inhibition did not affect the number of infiltrated neutrophils during bevacizumab treatment (Supplementary data Fig. 3C ). As reported previously (7, 27), we found the angiogenesis marker CD31 was markedly inhibited in both control cells and S100A4 depleted tumors following 4 weeks of bevacizumab treatment (Fig. 6B,   4 week), indicating the bevacizumab-treated tumor had not escaped from therapy at that time point. However, at 6 weeks tumors were bevacizumab resistant and demonstrated an increase in CD31 staining, which was not observed in the S100A4 depletion group (Fig. 6B, 6 week) .
Interestingly, YKL-40 staining was increased in bevacizumab treated tumors at as early as 4 weeks which was also inhibited by S100A4 down-regulation at 4 weeks and 6 weeks (Fig. 6C ).
These data suggest that the mesenchymal transformation of gliomas was regulated by S100A4 and may be responsible for the increase in angiogenesis during tumor progression on anti-VEGF therapy. 
Discussion
Glioblastoma is recognized as the most common and lethal form of brain cancer. Current treatments for glioblastoma include temozolomide (TMZ) paired with radiotherapy, and to more recently the use of antiangiogenic agents (28) . However, anti-VEGF agents have not significantly extended the life expectancies of patients diagnosed with glioblastoma (29, 30) , which has partially been attributed to drug resistance. The major aim of this study is to determine the mechanisms underlying glioblastoma resistance to antiangiogenic therapy.
Although there is strong preclinical evidence supporting the efficacy of antiangiogenic therapy, tumors eventually adopt a highly resistant phenotype. In this study, we demonstrate that neutrophils may play a critical role in tumor escape from antiangiogenic therapy. Consistent with previous studies (7), we observed an increase in neutrophil infiltration into gliomas, which may be partially driven by tumor hypoxia possibly exacerbated by prolonged anti-VEGF therapy (7, 31) . The extent of neutrophil infiltration was positively correlated with glioma grade. Our studies provide evidence that neutrophils promote the glioma malignant phenotype and increase the expression of mesenchymal markers in vitro and in vivo.
Neutrophils have been reported to play an important role in stimulating tumor angiogenesis (32, 33) . In patients with myxofibrosarcomas, increased numbers of neutrophils were associated with increased intratumoural microvessel density (34) . In vivo studies using various tumor models of angiogenesis demonstrated that neutrophils promote neovascularization (20, 21, 35) . In our angiogenesis by inducing a shift of gliomas from proneural to mesenchymal subtype (Fig. 6D) .
Although activated myeloid cells such as M2-skewed macrophages can directly secrete proangiogenic factors (36) (37) (38) (39) , tumor associated neutrophils may also regulate tumor angiogenesis in an indirect way, such as through shifting stem cells towards a mesenchymal phenotype.
In the present study, we found that a mesenchymal transformation in glioma stem cells was promoted by neutrophils through up-regulation of S100A4. S100A4 belongs to the S100 family of proteins that contain two Ca 2+ -binding sites including a canonical EF-hand motif (40) . S100A4 is involved in the regulation of a wide range of biological effects including cell motility, survival, differentiation and contractility (41) . Several of the S100A4 effects resemble processes that occur during epithelial-mesenchymal transition (EMT), and a direct link between S100A4 expression and EMT has been suggested in a number of organs (42) (43) (44) . In human cancer patients, increased expression of S100A4 is positively associated with an increased incidence of metastasis, invasiveness, aggressiveness, and a worse prognosis (45) (46) (47) (48) (49) (50) . Our mesenchymal glioblastoma stem cells expressed S100A4 whereas GICs with a proneural signature did not.
Likewise, a query of the Cancer Genome Atlas (TCGA) identified 5.8% of the glioblastoma samples (206 cases) over expressed S100A4 and most of these samples (58.6%) were of the mesenchymal subtype and associated with a shorter overall survival (P=0.003964). Conversely, 14.3% proneural glioblastoma samples have down-regulation of S100A4 and longer survival (P=0.009221). Consistent with our results that neutrophils can increased the expression of S100A4 in vitro, S100A4 and CD64, a human monocyte marker, are significantly co-expressed in glioblastoma patient samples from TCGA. Cumulatively, these data suggest that S100A4 may be a key contributor of mesenchymal transition in glioblastoma progression, and the increased expression of S100A4 can be at least partially promoted by an increase in neutrophil infiltration.
Research. 
Currently, it is difficult to discern the exact mechanisms underlying S100A4-mediated mesenchymal transformation because S100A4 can function both intra-and extra-cellularly. It is likely that the intracellular and the extracellular effects involve distinct mechanisms. S100A4 has been reported to interact with multiple proteins which are known to play a role in tumor progression and metastasis, such as MMP-9 (51). Iwamoto et al showed that glioblastoma patients with longitudinal increases in MMP-9 had a shorter survival (52) . Studies in endothelial cells and tumors demonstrate that S100A4 expression can be promoted by TGF-β1 (43, 53), which is well-known to induce EMT. Consistently, we have observed an increased the TGF-β pathway in anti-VEGF resistant tumors (7) . Further studies are needed to identify the molecular mechanism by which S100A4 regulate the mesenchymal phenotype.
Although tumor associated neutrophils play a critical role in tumor progression, therapeutic targeting of this cell type in cancer will be challenging. Neutrophils are critical mediators of host defense against infection, and depletion of these cells could result in dangerous levels of immunosuppression. However, we found that down-regulation of S100A4 inhibited neutrophilpromoting tumor progression independent of the infiltration of neutrophils. Our findings provide a possible alternative strategy to targeting the specific neutrophil-activated regulator on tumor cells, S100A4. Therefore, the combination of S100A4 inhibitor with standard anti-angiogenesis therapy may inhibit glioma progression and anti-VEGF therapy resistance. 
